{"protocolSection":{"identificationModule":{"nctId":"NCT06078215","orgStudyIdInfo":{"id":"392/2023"},"organization":{"fullName":"Poznan University of Medical Sciences","class":"OTHER"},"briefTitle":"CERebrolysine Effect on Blood-brain Barrier in acUte Ischemic Stroke","officialTitle":"CERebrolysine Effect on Blood-brain Barrier / Endothelium Integrity During Reperfusion Therapy of acUte Ischemic Stroke (CERBERUS Study)","acronym":"CERBERUS"},"statusModule":{"statusVerifiedDate":"2023-10","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-01-10","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-01-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2025-03-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-10-05","studyFirstSubmitQcDate":"2023-10-05","studyFirstPostDateStruct":{"date":"2023-10-11","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-10-11","lastUpdatePostDateStruct":{"date":"2023-10-13","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Poznan University of Medical Sciences","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The study investigates whether Cerebrolysin stabilizes blood-brain barrier integrity in a manner that can be monitored using serum levels of the principal tight junction proteins, e.g., occludin (OCL), claudin-5 (CLN), and zonula occludens-1 (ZO-1), or other molecules known to be involved in BBB degradation, e.g., S100B and whether it protects against hemorrhagic transformation in ischemic stroke patients after reperfusion therapy (i.e. thrombolysis and/or mechanical thrombectomy).","detailedDescription":"Hemorrhagic transformation (HT) of ischemic stroke can be identified in 3-40% of patients. The incidence varies depending on the definition used and the studied population. The severity of HT can be described using clinical and radiological tools and classified as asymptomatic/symptomatic, according to European Cooperative Acute Stroke Study classification and Heidelberg Bleeding Classification. Breakdown of the blood-brain barrier (BBB) is associated with an increased risk of developing a hemorrhagic transformation (HT) of ischemic stroke. In patients who received reperfusion therapy (thrombolysis, mechanical thrombectomy), secondary HT had a negative influence on the clinical course and outcome.\n\nTight junction (TJ) proteins are important cell adhesion components that stabilize endothelium cells lining and are responsible for maintaining the BBB integrity.\n\nBiomarkers of BBB damage that can be evaluated during the early phases of stroke might be useful for predicting the risk of HT. Such biomarkers could also facilitate the decision of whether to begin thrombolytic therapy in acute ischemic stroke patients. Experimental data support the evidence for protective effect of Cerebrolysin on BBB integrity. Moreover, it diminished and reversed negative effect of recombinant tissue plasminogen activator (rtPA) used as thrombolytic agent on endothelial cells integrity. Cerebrolysin stabilized tight junction proteins expression: occludin, claudin-5 and zona occludens 1 (ZO1). In our previous study we have found that circulating TJs predict HT in ischemic stroke patients. Clinically evident HTs were associated with increased concentrations of occludin and S100B, an increase in the claudin-5/ZO-1 ratio, and a decreased level of vascular endothelial growth factor (VEGF). Claudin-5 levels also correlated with HT occurrence when estimated within 3 hours of stroke onset. The protective effects of Cerebrolysin were already clinically evidenced, however there are no available studies using biomarkers of BBB.\n\nAim of the study\n\nWe aim to investigate whether Cerebrolysin stabilizes BBB integrity in a manner that can be monitored using serum levels of the principal TJ proteins, e.g., occludin (OCL), claudin-5 (CLN), and zonula occludens-1 (ZO-1), or other molecules known to be involved in BBB degradation, e.g., S100B and whether it protects against HT in ischemic stroke patients after reperfusion therapy.\n\nStudy design\n\nA prospective longitudinal study will be performed in ischemic stroke patients who:\n\n1. are included for reperfusion therapy (intravenous thrombolysis and/or mechanical thrombectomy - control (group A),\n2. are included for reperfusion therapy (intravenous thrombolysis and/or mechanical thrombectomy plus Cerebrolysin (group B)\n3. are not referred to reperfusion therapy nor Cerebrolysin (group C).\n\nAll patients with NIHSS score \\> 8 will receive 30 ml Cerebrolysin in 500 ml of buffered crystalloid solution intravenously initiated within 12 hours from symptoms onset.\n\nWhole blood samples will be withdrawn at the admission, then within 1 to 3 days after stroke onset and at 7th day after stroke onset or when the endpoint will be reached by the patient. Occludin, claudin 5 and ZO-1 concentrations will be analyzed by means of home-made enzyme-linked immunosorbent assay.\n\nEndpoint will include clinical worsening (increase in the NIHSS by \\> 4 points), radiologically evident hemorrhage or radiologically evident brain edema at control CT performed within 1 to 3 days after stroke onset.\n\nStandard head CT will be performed in all patients at the admission, within 1 to 3 days after stroke onset, after worsening of clinical status and additionally when the differentiation between hemorrhage and contrast staining will be required in thrombectomy patients. Hemorrhagic transformation of ischemic stroke will be classified according to Table 1.\n\nClinimetric evaluation of all patients will include NIHSS every day for 7 days and at day 30. Modified Rankin scale (mRS) will be evaluated at visit 1,2,3,4 and 5; Barthel index at visit 4 and 5 and Montreal Cognitive Assessment Test at visit 5.\n\nAll patents will undergo current American Heart Association Guidelines for the Early Management of Patients with Acute Ischemic Stroke.\n\nExpected results It is expected that Cerebrolysin can stabilize blood-brain barrier in ischemic stroke patients treated with reperfusion therapies via remodelling of tight junction proteins between endothelial cells. Such an effect measured by the levels of circulating tight junction proteins can translate into prevention of hemorrhagic transformation. To summarize, Cerebrolysine can guard blood-brain barrier integrity in ischemic stroke (Cerberus effect)."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"],"keywords":["Acute Ischemic Stroke","blood-brain barrier","cerebrolysin"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"A prospective longitudinal study will be performed in ischemic stroke patients who:\n\n1. are included for reperfusion therapy (intravenous thrombolysis and/or mechanical thrombectomy - control (group A),\n2. are included for reperfusion therapy (intravenous thrombolysis and/or mechanical thrombectomy plus Cerebrolysin (group B)\n3. are not referred to reperfusion therapy nor Cerebrolysin (group C).","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":350,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Thrombolysis and/or mechanical thrombectomy","type":"NO_INTERVENTION","description":"patients included for reperfusion therapy (intravenous thrombolysis and/or mechanical thrombectomy - comparator"},{"label":"Cerebrolysin","type":"EXPERIMENTAL","description":"patients included for reperfusion therapy (intravenous thrombolysis and/or mechanical thrombectomy and treated with Cerebrolysin","interventionNames":["Combination Product: Cerebrolysin"]},{"label":"No reperfusion therapy / no cerebrolysin","type":"NO_INTERVENTION","description":"patients not referred to reperfusion therapy nor Cerebrolysin"}],"interventions":[{"type":"COMBINATION_PRODUCT","name":"Cerebrolysin","description":"Intravenous infusion of 30 ml Cerebrolysine in 500 ml of buffered crystalloid solution intravenously initiated within 12 hours from symptoms onset","armGroupLabels":["Cerebrolysin"],"otherNames":["FPF (Fine Particle Fraction)-1070"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"National Institute of Health Stroke Scale","description":"National Institute of Health Stroke Scale; score range: 1-42; 1-4 - Minor stroke; 5-15 - Moderate stroke; 16-20 - Moderate to severe stroke; 21-42 - Severe stroke","timeFrame":"every day for 7 days after stroke onset"},{"measure":"National Institute of Health Stroke Scale","description":"National Institute of Health Stroke Scale; score range: 1-42; 1-4 - Minor stroke; 5-15 - Moderate stroke; 16-20 - Moderate to severe stroke; 21-42 - Severe stroke","timeFrame":"at day 30 after stroke onset"},{"measure":"Detection of hemorrhagic transformation [range o:1]","description":"hemorrhagic transformation on head computerized tomography","timeFrame":"within 1 to 3 days after stroke onset, after worsening of clinical status by more than 4 points in NIHSS"},{"measure":"Concentration of plasma occludin [ng/mL]","description":"Occludin is an enzyme (EC 1.6) that oxidizes NADH (Nicotinamide adenine dinucleotide)","timeFrame":"at the admission, within 1 to 3 days after stroke onset"},{"measure":"Concentration of plasma occludin [ng/mL]","description":"Occludin is an enzyme (EC 1.6) that oxidizes NADH (Nicotinamide adenine dinucleotide)","timeFrame":"at 7th day after stroke onset"},{"measure":"Concentration of plasma claudin 5 [ng/mL]","description":"Claudins are small (20-24/27 kilodalton (kDa)) transmembrane proteins.","timeFrame":"at the admission, within 1 to 3 days after stroke onset"},{"measure":"Concentration of plasma claudin 5 [ng/mL]","description":"Claudins are small (20-24/27 kilodalton (kDa)) transmembrane proteins.","timeFrame":"at 7th day after stroke onset"},{"measure":"Concentration of plasma ZO1 [ng/mL]","description":"Zonula occludens-1 ZO-1, also known as Tight junction protein-1","timeFrame":"at the admission, within 1 to 3 days after stroke onset"},{"measure":"Concentration of plasma ZO1 [ng/mL]","description":"Zonula occludens-1 ZO-1, also known as Tight junction protein-1","timeFrame":"at 7th day after stroke onset"}],"secondaryOutcomes":[{"measure":"Modified Rankin scale [range 0:6]","description":"Modified Rankin scale; 0-2 - good functional outcome; 3-6 - poor functional outcome","timeFrame":"at the admission, within 1 to 3 days after stroke onset"},{"measure":"Modified Rankin scale [range 0:6]","description":"Modified Rankin scale; 0-2 - good functional outcome; 3-6 - poor functional outcome","timeFrame":"at 7th day after stroke onset"},{"measure":"Modified Rankin scale [range 0:6]","description":"Modified Rankin scale; 0-2 - good functional outcome; 3-6 - poor functional outcome","timeFrame":"at the 30th +/- 5 day after stroke onset"},{"measure":"Modified Rankin scale [range 0:6]","description":"Modified Rankin scale; 0-2 - good functional outcome; 3-6 - poor functional outcome","timeFrame":"at 90th +/- 5 day after stroke onset"},{"measure":"Barthel Index for Activities of Daily Living (ADL) [range 0:100]","description":"measures the degree of assistance required by an individual; 0-20 - total dependency, 21-60 - severe dependency, 61-90 - moderate dependency, 91-100 - slight dependency","timeFrame":"30th +/- 5 day after stroke onset"},{"measure":"Barthel Index for Activities of Daily Living (ADL) [range 0:100]","description":"measures the degree of assistance required by an individual; 0-20 - total dependency, 21-60 - severe dependency, 61-90 - moderate dependency, 91-100 - slight dependency","timeFrame":"at the 90th +/- 5 day after stroke onset"},{"measure":"Death [range 0:1]","description":"survival measure","timeFrame":"within 90 days after stroke onset"},{"measure":"Montreal Cognitive Assessment Test [range 0:30]","description":"the assessment of cognitive functions; 26-30 - normal cognition, 18-25 - mild cognitive impairment, 10-17 - moderate cognitive impairment, \\<10 - severe cognitive impairment","timeFrame":"at the 90th +/-5 day after stroke onset"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* acute ischemic stroke patients\n* informed consent\n\nExclusion Criteria:\n\n* no informed consent\n* primary or metastatic brain tumor\n* brain abscess\n* encephalitis\n* localized inflammation\n* sepsis\n* autoimmune diseases of central or peripheral nervous system\n* Cerebrolysin hypersensitivity / allergy\n* epilepsy\n* severe kidney disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Slawomir Michalak, Prof.","role":"CONTACT","phone":"+48 61 8691 535","email":"swami@ump.edu.pl"},{"name":"Joanna Rybacka-Mossakowska, MD, PhD","role":"CONTACT","phone":"+48 61 8691 459","email":"joannarybacka@gmail.com"}],"overallOfficials":[{"name":"Slawomir Michalak, Prof.","affiliation":"Poznan University of Medical Sciences","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"University Hospital","status":"RECRUITING","city":"PoznaÅ„","zip":"60-355","country":"Poland","contacts":[{"name":"Slawomir Michalak, Prof.","role":"CONTACT","phone":"+4861 8691 535","email":"swami@ump.edu.pl"},{"name":"Joanna Rybacka-Mossakowska, MD, PhD","role":"CONTACT","phone":"+4861 8691 458","email":"joannarybacka@gmail.com"},{"name":"Jacek Namysl, MD","role":"SUB_INVESTIGATOR"},{"name":"Joanna Rybacka-Mossakowska, MD, PhD","role":"SUB_INVESTIGATOR"},{"name":"Slawomir Michalak, Prof.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":52.40692,"lon":16.92993}}]},"referencesModule":{"references":[{"pmid":"22993287","type":"BACKGROUND","citation":"Kazmierski R, Michalak S, Wencel-Warot A, Nowinski WL. Serum tight-junction proteins predict hemorrhagic transformation in ischemic stroke patients. Neurology. 2012 Oct 16;79(16):1677-85. doi: 10.1212/WNL.0b013e31826e9a83. Epub 2012 Sep 19."},{"pmid":"34214867","type":"BACKGROUND","citation":"Poljakovic Z, Supe S, Ljevak J, Starcevic K, Peric I, Blazevic N, Krbot-Skoric M, Jovanovic I, Ozretic D. Efficacy and safety of Cerebrolysin after futile recanalisation therapy in patients with severe stroke. Clin Neurol Neurosurg. 2021 Aug;207:106767. doi: 10.1016/j.clineuro.2021.106767. Epub 2021 Jun 18."},{"pmid":"33661804","type":"BACKGROUND","citation":"Teng H, Li C, Zhang Y, Lu M, Chopp M, Zhang ZG, Melcher-Mourgas M, Fleckenstein B. Therapeutic effect of Cerebrolysin on reducing impaired cerebral endothelial cell permeability. Neuroreport. 2021 Mar 24;32(5):359-366. doi: 10.1097/WNR.0000000000001598."},{"pmid":"16219824","type":"BACKGROUND","citation":"Kassner A, Roberts T, Taylor K, Silver F, Mikulis D. Prediction of hemorrhage in acute ischemic stroke using permeability MR imaging. AJNR Am J Neuroradiol. 2005 Oct;26(9):2213-7."},{"pmid":"30499355","type":"BACKGROUND","citation":"Zhang Y, Chopp M, Zhang ZG, Zhang Y, Zhang L, Lu M, Zhang T, Winter S, Doppler E, Brandstaetter H, Mahmood A, Xiong Y. Cerebrolysin Reduces Astrogliosis and Axonal Injury and Enhances Neurogenesis in Rats After Closed Head Injury. Neurorehabil Neural Repair. 2019 Jan;33(1):15-26. doi: 10.1177/1545968318809916. Epub 2018 Nov 30."},{"pmid":"23009193","type":"BACKGROUND","citation":"Lang W, Stadler CH, Poljakovic Z, Fleet D; Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke. Int J Stroke. 2013 Feb;8(2):95-104. doi: 10.1111/j.1747-4949.2012.00901.x. Epub 2012 Sep 26."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000006952","term":"Cerebrolysin"}],"ancestors":[{"id":"D000018696","term":"Neuroprotective Agents"},{"id":"D000020011","term":"Protective Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000018697","term":"Nootropic Agents"}],"browseLeaves":[{"id":"M21550","name":"Pharmaceutical Solutions","relevance":"LOW"},{"id":"M351658","name":"Cerebrolysin","asFound":"VII","relevance":"HIGH"},{"id":"M20463","name":"Neuroprotective Agents","relevance":"LOW"},{"id":"M21559","name":"Protective Agents","relevance":"LOW"},{"id":"M20464","name":"Nootropic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"PhSol","name":"Pharmaceutical Solutions"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"NeuroAg","name":"Neuroprotective Agents"},{"abbrev":"NootAg","name":"Nootropic Agents"}]}},"hasResults":false}